Erste Asset Management’s Cytokinetics CYTK Stock Holding History

Erste Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.53M	Buy	109,183 +32,233	+42%	+$2.31M	0.07%	227
2026 Q1	$4.85M	Hold	76,950	–	–	0.04%	274
2025 Q4	$4.75M	Hold	76,950	–	–	0.04%	278
2025 Q3	$4.15M	Hold	76,950	–	–	0.04%	275
2025 Q2	$2.55M	Buy	76,950 +16,500	+27%	+$574K	0.02%	364
2025 Q1	$2.61M	Hold	60,450	–	–	0.03%	282
2024 Q4	$2.86M	Hold	60,450	–	–	0.04%	284
2024 Q3	$3.16M	Hold	60,450	–	–	0.04%	276
2024 Q2	$3.25M	Hold	60,450	–	–	0.04%	267
2024 Q1	$4.32M	Buy	60,450 +23,000	+61%	+$1.78M	0.06%	244
2023 Q4	$3.12M	Buy	37,450 +19,000	+103%	+$688K	0.05%	260
2023 Q3	$568K	Hold	18,450	–	–	0.01%	394
2023 Q2	$604K	Hold	18,450	–	–	0.01%	401
2023 Q1	$631K	Hold	18,450	–	–	0.01%	406
2022 Q4	$843K	Hold	18,450	–	–	0.02%	375
2022 Q3	$903K	Hold	18,450	–	–	0.02%	366
2022 Q2	$899K	Hold	18,450	–	–	0.02%	370
2022 Q1	$674K	Sell	18,450 -4,150	-18%	-$147K	0.01%	405
2021 Q4	$1.05M	Buy	+22,600	New	+$872K	0.02%	353

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management's CYTK Position: Q2 2026 in Review

Erste Asset Management increased its Cytokinetics (CYTK) stake by 42% in Q2 2026, buying an estimated $2.31M and bringing the position to 109,183 shares worth $9.53M. The position accounts for 0.07% of the portfolio, ranked #227.

Erste Asset Management first reported a position in CYTK in Q4 2021 and has held it in 19 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Erste Asset Management held 109,183 shares of Cytokinetics worth $9.53M as of Q2 2026.
Erste Asset Management bought 32,233 Cytokinetics shares in Q2 2026, an estimated $2.31M.
Cytokinetics made up 0.07% of Erste Asset Management's portfolio in Q2 2026, its #227 holding.
Erste Asset Management first reported a position in Cytokinetics in Q4 2021 and has held it in 19 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.